Can We Better Predict Who Is Most Likely to Have Another VTE After a First Event? – RPTH Journal
RPTH Journal shared a post on LinkedIn about a recent article by Eugenia Biguzzi, adding:
”Can we better predict who is most likely to have another VTE after a first event?
A new RPTH study suggests that combining d-dimer with thrombin generation may improve risk stratification for recurrent venous thromboembolism. In this cohort of 1,895 patients, recurrence risk was lowest in those with low d-dimer + low thrombin generation, intermediate when only 1 marker was elevated, and highest when both were elevated.
The signal was especially striking in unprovoked VTE. Patients with high d-dimer and high thrombin generation had an incidence rate of 9.80 per 100 patient-years, compared with 1.36 per 100 patient-years in those with low levels of both markers, with an adjusted hazard ratio of 8.59.
Why this matters:
Extending anticoagulation lowers recurrence risk, but bleeding risk remains the tradeoff. Tools that better separate low-, intermediate-, and high-risk patients could help guide more personalized decisions after a first VTE.
A key caveat: thrombin generation was measured with a specialized assay, which may limit immediate routine clinical use. Still, this study adds to the push toward biomarker-guided anticoagulation decisions rather than relying on broad clinical categories alone.”
Title: Recurrent venous thromboembolism: association with thrombin generation and d-dimer
Authors: Eugenia Biguzzi, Kristien Winckers, Tilman M. Hackeng, Frits R. Rosendaal, Astrid van Hylckama Vlieg
Read the Full Article on RPTH
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 12, 2026, 13:18Gareth Owens: Advancing Aortic Disease Awareness Through Think Aorta
-
Apr 12, 2026, 13:11Denis Oduor: Apheresis Donation and Blood Component Therapy
-
Apr 12, 2026, 13:04Arsene Mekinian Featured in the Journal of Internal Medicine – Santé Arménie
-
Apr 12, 2026, 13:04Toward Nationwide Hemophilia Care in Armenia by 2030 – WFH
-
Apr 12, 2026, 12:56Chokri Ben Lamine: Clinical Dosing and Special Populations Guide for Apixaban
-
Apr 12, 2026, 12:04Riccardo Fumagalli: Long Term Complications Following Catheter Directed Thrombolysis in PE
-
Apr 12, 2026, 11:36Ifeanyichukwu Ifechidere: From Running Tests to Trusting Interpretation in Coagulation
-
Apr 12, 2026, 11:30Zack Rosanova: What Happens to Your Brain Without Sleep
-
Apr 11, 2026, 13:51David McIntosh: Vital Plasma Derived Medicines – The Anomalous UK Scene